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Abstract
Background. Muscle strain during physical exercise may lead to muscle damage and hyperkalaemia. Commonly 
prescribed drugs including statins and angiotensin-converting enzyme inhibitors (ACEI) may increase serum potas-
sium and cause muscle damage. We postulated that the risk may be even higher if the patients are treated with a 
combination of statin and ACEI. 
The aim of the study was to compare the effect of moderate intensity short-term physical exercise on the changes of 
muscle injury markers serum carbonic anhydrase 3 and creatine kinase in patients with arterial hypertension receiv-
ing ACEI and statin.
Material and methods. Eighteen patients with arterial hypertension treated with ACEI were included in a prospec-
tive placebo-controlled cross-over study. 18 healthy individuals served as controls. Hypertensive patients underwent 
30-minute exercise test, which was repeated two times in a random order after the administration of ACEI with 
statin or ACEI with placebo. Each treatment period lasted 8 weeks separated by 2-week wash-out. Normotensive 
subjects underwent a single exercise test. Serum carbonic anhydrase 3 (CAIII) and creatine kinase (CK) activity were 
measured before and after exercise and recovery.
Results. At baseline and during the exercise CAIII was significantly higher in healthy volunteers compared to hyper-
tensive patients. CAIII increased significantly during exercise only after treatment with both ACEI and statin. Serum 
CK was higher in hypertensive patients treated with ACEI plus statin during all exercise tests. 
Conclusions. Addition of statin to ACEI in patients with arterial hypertension does not increase the risk of muscle 
damage during moderate intensity short-term physical exercise.
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Introduction
Exercise-induced muscle damage is the consequence 
of a complex interactions of events, which seem to 
include muscle fibres damage due to myofibril injury 
(rupture of myofibrils), impaired excitation-contrac-
tion coupling associated with local ATP depletion, 
changes in the intracellular calcium homeostasis, oxi-
dative stress and inflammation [1]. Vigorous physical 
exercise may affect the integrity of muscle cells and 
cause a release of muscle cell enzymes into the extra-
cellular compartment. Muscle damage is a frequent 
event and many individuals are susceptible to muscle 
damage induced by physical exercise or caused by 
pharmacotherapy [2–4]. Serum concentration of 
creatine kinase and myoglobin are sensitive markers 
of muscle damage and myopathy [5, 6]. Creatine 
kinase (CK) is an enzyme expressed in large amounts 
in muscle cells. It catalyses the reversible process of 
transferring the phosphate group from phosphocre-
atine to adenosine diphosphate (ADP) thus rebuild-
ing the adenosine diphosphate (ATP) inventory. The 
concentration of creatine kinase increases manifolds 
after the skeletal muscle damage caused by trauma, 
intramuscular drug injection, intense physical exer-
cise, convulsions, myositis, muscular dystrophies and 
myotonia [7, 8].
Serum carbonic anhydrase III has been a well-es-
tablished serum marker of skeletal muscle damage. 
Carbonic anhydrase 3 is a metalloenzyme found in 
the cytosol of a body cell. It catalyses the enzymatic 
reaction of hydrogen ion formation from water and 
carbon dioxide [9]. The enzyme was first detected 
in human skeletal muscle cells in 1979 [10–12]. 
Carbonic anhydrase 3 is selectively expressed in 
skeletal muscle, but not in the heart muscle, which 
was used in the differential diagnosis of steno-
cardia; however, a clinical interest in the routine 
measurement of this marker has diminished after 
the introduction of highly sensitive markers of 
myocardial ischaemia [13]. A significant increase 
in carbonic anhydrase 3 activity in the blood was 
reported after physical exercise and in several neu-
romuscular diseases that resulted in microdamage 
of muscle cells [14, 15].
Most patients with multiple coexisting diseases 
including arterial hypertension or coronary artery 
disease require an administration of statin. Taking 
into account a large proportion of patients treated 
with statins and the changes of lifestyle that have 
occurred in the modern societies aimed at increasing 
recreational physical activity including short-term 
and prolonged high-intensity exercises the potential 
risk of such adverse effects as hyperkalaemia and 
muscle damage of these drugs is becoming clinically 
relevant [11, 12].
The aim of the study was to assess the effect of 
a moderate intensity short-term standardized physi-
cal exercise on the changes of serum creatine kinase 
and carbonic anhydrase III activity in patients with 
arterial hypertension treated with an angiotensin-
converting enzyme inhibitor alone or in a combina-
tion with statin.
Material and methods
In a prospective, cross-over and placebo-controlled 
study 18 patients with essential hypertension and 18 
healthy individuals who served as a control group 
were included. The study design is presented in 
Figure 1.
The study protocol was approved by the Local 
Bioethics Committee. All subjects gave a written 
informed consent for the participation in the study.
The inclusion criteria were as follows: arterial hy-
pertension diagnosed according to the 2013 ESH/ 
/ESC criteria [17], previously untreated or treated 
with maximum two antihypertensive drugs in thera-
peutic doses, women or men aged 18–70 years, se-
rum potassium concentration less than 5.2 mmol/l at 
the time of screening, total cholesterol > 190 mg/dL 
or LDL-cholesterol >115 mg/dL.
The exclusion criteria included any secondary 
form of hypertension, motor organ disorders, in-
herited hypercholesterolemia, uncontrolled symp-
tomatic heart failure (NYHA III and IV), uncon-
trolled arrhythmia, atrioventricular block II∞ or III∞, 
symptomatic aortic stenosis, history of myocarditis 
or pericarditis, acute infections, hyperthyroidism, 
chronic kidney disease stage 3A or higher, i.e. es-
timated glomerular filtration rate calculated using 
the CKD-EPI [18] formula equal or smaller than 
60 mL/min/1.73 m2, serum potassium higher than 
5.5 mmol/L found at least twice at any time in the 
past, history of statin intolerance, uncontrolled dia-
betes mellitus, chronic liver disease, mental illness, 
history of non-compliance.
Exercise tests were conducted on a bicycle ergom-
eter (Kettler Stratos, Ense-Parsit, Germany) follow-
ing the same protocol in all participants. Each time, 
the exercise followed 20-minute preparation includ-
ing the rest in a sitting position. A peripheral venous 
catheter was placed to withdraw blood for laboratory 
measurements. After a baseline blood sample was 
taken, the patients started the exercise that lasted 30 
minutes with a load to achieve oxygen consumption 
in the range of 55–60% maximum based on the 
arterial hypertension 2019, vol. 23, no. 4
258 www.ah.viamedica.pl
heart rate. After 15 and 30 minutes, blood samples 
were taken for laboratory tests. Upon the completion 
of exercise, the patients were asked to spend another 
30 minutes in a sitting position to recover. After 30 
minutes of the rest that followed the exercise the last 
blood sample was taken. During each examination 
the patients were asked to drink 500 mL of still low-
mineralized water. The blood samples after the for-
mation of blood clot were immediately centrifuged, 
and the serum was separated into separate test tubes 
frozen at –80∞C until laboratory measurements.
Creatine kinase was measured in plasma by the 
kinetic method using a Cobas Integra 400 Plus bio-
chemical analyser (Roche, Munich, Germany). 
Carbonic anhydrase 3 was measured in plasma 
by the immunoenzymatic method using the Cloud 
Clone Corp test. (Houston, USA).
All patients from the study group had been receiv-
ing a stable dose of ramipril 10 mg each morning for 
at least 6 months before the study. The whole study 
lasted 18 weeks and was divided into 3 stages. After 
the first exercise test, the patients were randomly 
divided into two groups. An even parity of the num-
bers generated in MS Excel using RAND function 
was used for randomization.
During the first 8-week study period the patients 
received simvastatin in a dose of 40 mg or placebo 
depending on the treatment order of the group. 
The drug and placebo were prepared by the hospital 
pharmacy in a form of tablets in identical appear-
ance as the active drug. After 8 weeks of treatment, 
during which the study visits were held every 2 
weeks the second exercise test was carried out fol-
lowing exactly the same scheme. The second test 
was followed by a wash-out period during which 
the study drug test or placebo were discontinued 
for two weeks. The wash-out period was followed 
by the third period lasting 8 weeks during which 
the patients received either drug or placebo. At the 
end of that period the patients underwent the third 
exercise test. The adherence to the therapy was veri-
fied by the counting of the packages and tablets of 
medicines returned by the patients at each visit. In 
a group of 18 healthy volunteers who were not tak-
ing any drugs the exercise test was carried out once 
according to the same protocol. The creatine kinase 
and carbonic anhydrase III activity were measured 
before each exercise test and immediately at its end 
and after a rest period.
Descriptive statistics included a calculation of 
the arithmetic mean and standard deviation (SD). 
Normality of the distribution of variables was ex-
amined with the Shapiro-Wilk test. Means of both 
groups were compared with two-sided t-test or 
Mann-Whitney test depending on the distribution 
of each variable. ANOVA was used to analyse re-
peated measurements. p < 0.05 was taken as statisti-
cally significant.
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Figure 1. Study design and flowchart. ECG — electrocardiography
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Results
All initially qualified patients completed the study. 
None of participants reported any adverse reaction 
to the study drugs that led to the withdrawal of the 
treatment. Serum creatine kinase and carbonic an-
hydrase III activity both at the rest and during the 
physical exercise remained within the normal range 
in both groups.
The results of serum creatine kinase activity mea-
surements are shown in Table I. There were sig-
nificant differences in serum creatine kinase activity 
between the patients receiving ACEI and statin and 
patients treated only with ACEI or healthy volun-
teers at baseline and during the exercise test and 
after recovery (p < 0.05). The serum creatine kinase 
activity was higher in hypertensive patients treated 
ACEI combined with statin compared to the patients 
treated with ACEI only or healthy volunteers. There 
were no significant changes of creatinine kinase dur-
ing the exercise in each group.
The carbonic anhydrase 3 serum activity is shown 
in Table II. The activity was significantly higher in 
the control group compared to the hypertensive pa-
tients treated with ACEI or with both ACEI and 
statin with the exception of ACEI plus statin group 
after 30-minute recovery where the difference was 
not significant (p < 0.05). 
Figure 2 shows the percentage changes of carbonic 
anhydrase activity 3 during the short-term physical 
exercise in all parts of the study. The largest increase 
in the carbonic anhydrase 3 activity was found in 
patients treated with both ramipril and simvastatin. 
In the control group, the carbonic anhydrase 3 activ-
ity decreased during the exercise but later after the 
recovery a small nominal increase was noted.
Discussion
The main result of our study is the demonstration of 
the lack of an increased risk of muscle damage after 
the administration of the combination of statin and 
ACEI in hypertensive patients during a moderate 
short-term physical exercise.
During the treatment with statin, muscle damage 
was frequently reported, manifested mostly by a mus-
cle pain associated with modest or mild increase in 
the serum markers of muscle damage, e.g. serum 
creatine kinase [19–21]. No clinical symptoms that 
might have suggested statin-induced muscle damage 
were seen in our patients during the study and the 
physical exercise was very well-tolerated. 
Previously the incidents of the severe complica-
tion of statin therapy including rhabdomyolysis and 
severe hyperkalaemia and renal failure have also been 
reported [16, 22]. A rhabdomyolysis was described 
mostly after a mechanical muscle damage including 
intramuscular injections leading to muscle damage 
[23]. 
Post-exercise muscle damage usually does not re-
sult in any relevant clinical consequences and re-
mains subclinical but could be detected as an increase 
in specific serum markers of muscle damage deter-
mined in laboratory tests. Only in extreme cases it 
can lead to rhabdomyolysis. Rhabdomyolysis after 
Table I. Serum creatine kinase activity (before exercise, after 30-min exercise, after 30-min recovery) 
Before exercise  
[IU/L]
After 30-min exercise  
[IU/L]
After 30-min recovery  
[IU/L]
ACEI 59 ± 34 59 ± 27 58 ± 26
ACEI + statin 88 ± 62 94 ± 51 90 ± 62
ACEI + placebo 62 ± 32 68 ± 33 68 ± 27
Control group 48 ± 24 55 ± 31 51 ± 30
ACEI — angiotensin converting enzyme inhibitor 
Table II. Serum carbonic anhydrase 3 activity (p < 0.05), (before exercise, after 30-min exercise, after 30-min recovery)
Before exercise  
[IU/L]
After 30-min exercise  
[IU/L]
After 30-min recovery  
[IU/L]
ACEI 15475 ± 8304 17326 ± 11628 19419 ± 21159
ACEI + statin 18412 ± 92556 18101 ± 12228 26585 ± 23537
ACEI + placebo 14619 ± 9093 15744 ± 5736 15419 ± 9662
Control group 38122 ± 24333 32800 ± 25163 33699 ± 34927
ACEI — angiotensin converting enzyme inhibitor
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physical exercise was also reported in healthy athletes 
not taking any drugs and in the amateurs taking part 
in recreational sport activities. Most of the affected 
subjects were marathon runners, cyclists and those 
practicing other exhausting disciplines in unfavour-
able weather conditions [24–27]. However, the in-
formation about the risk of such events in a general 
hypertensive population is missing. Therefore we 
were not able to directly compare our results with 
the results of other authors. 
The choice of a particular statin for the study also 
needs to be discussed. In our study, simvastatin in 
a dose of 40 mg/day was used and the treatment 
duration was 8 weeks. We choose simvastatin for 
the study due to its common use in our country 
[28]. Simvastatin has a good safety profile and does 
not need to be reduced in mild renal function im-
pairment that is commonly seen in hypertensive 
patients. 
In order to evaluate the muscle damage each 
participant was first asked about the history of 
episodes of muscle weakness and myalgia and un-
explained changes in urine colour. It has been re-
ported that such symptoms may occur in 7–29% 
of statin-treated patients, although most often in 
those receiving the highest recommended doses of 
the drug [29].
Muscle cell damage can lead to a release of numer-
ous substances specifically expressed in the skeletal 
muscle cells into the blood, including ions and en-
zymes. Among them such markers as creatine kinase, 
myoglobin and skeletal muscle-specific carbonic an-
hydrase III have been best studied [14, 15].
The mean creatine kinase activity remained within 
the normal range in our patients during the whole 
study. Despite that we found that creatine kinase 
activity in hypertensive patients was significantly 
higher in patients treated with ramipril combined 
with simvastatin when compared to the treatment 
with ACEI alone. This may suggest the effect of 
statins on the subclinical muscle cell damage. The 
lack of any significant increase in muscle damage 
markers in hypertensive patients who received only 
an ACEI may suggest that the effect could be at-
tributed only to a statin. We have also looked at the 
post-exercise changes of muscle damage markers and 
we found a small non-significant numerical increase 
in these markers during the recovery from exercise. 
Even small changes in creatine kinase activity dur-
ing exercise seem to confirm the effect of exercise 
on the integrity of muscle cells, which is consistent 
with earlier studies performed by other authors but 
in different populations and different experimental 
conditions [30, 31].
The determination of serum creatine kinase activ-
ity alone, although common in clinical practice may 
be insufficient since often even in patients reporting 
the symptoms indicative of myalgia, there is no de-
tectable increase in the serum activity of this enzyme 
[32]. That is why we decided to determine also the 
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Figure 2. Percentage changes of carbonic anhydrase 3 activity from baseline during the exercise test. ACEI — angiotensin converting 
enzyme inhibitor
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activity of carbonic anhydrase 3 that is a more selec-
tive and sensitive marker of muscle damage [15, 33].
In the available literature a significant increase in 
carbonic anhydrase 3 activity was described in several 
conditions leading to overload and muscle damage 
[14, 15]. 
To maximize the safety of the patients, we decided 
to choose the intensity and duration of physical exer-
cise that would be well tolerated by the patients and 
remain in a range mimicking recreational physical 
activity. Each time during the study, the participants 
were asked to drink 500 ml of low-mineralized water 
for proper hydration in order to maintain adequate 
diuresis and reducing the risk of dehydration [34]. 
Despite the small group size the study had a cross-
over design to increase the statistical power by al-
lowing the intra-group comparisons, as each patient 
received both study drugs and a placebo. The subjects 
were also carefully selected to ensure the homogene-
ity of the population. 
The low number of study participants was also the 
result of long study protocol, which included at least 
a six-month period of ramipril treatment at a dose 
of 10 mg/24 h before the start of exercise tests, and 
then a total of ten-week treatment after randomisa-
tion. For safety reason we excluded the patients with 
chronic kidney disease stage 3a and higher. In such 
patients, the expected risk of complications includ-
ing severe hyperkalaemia resulting from renal failure 
may have been much higher reported as high as 50% 
in some studies [35]. In addition, the patients with 
a creatinine clearance below 60 mL/min/m2 require 
a reduction of the dose of ramipril and or statin, 
which could hinder the interpretation of our results.
Our results may have some implications for clini-
cal practice in frequent cases of the treatment of 
hypertensive patients with the combination of ACEI 
and statin. Our results suggest that such the combi-
nation has a favourable safety profile. 
Conclusions
Moderate physical exercise in hypertensive patients 
treated with an angiotensin-converting enzyme in-
hibitor in combination with statin seems to be safe 
and does not increase the risk of clinically significant 
muscle damage.
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